Skip to main content

Table 5 Summary of participants with PCSA (parameters with PCSA definitions) for clinical chemistry and haematology parameters during the single dose study

From: Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection

Laboratory blood parameters (PCSA definition)

Normal range

Single Dose Study

  

Placebo

Ferroquine

  

(N = 10)

400 mg (N = 6)

800 mg (N = 6)

1200 mg (N = 6)

1400 mg (N = 6)

1600 mg (N = 6)

Eosinophils (> max (0.5 Giga/L, ULN))

0-1320/μl

6

5

1

3

6

5

Haemoglobin (decrease≥ 2 g/dL versus baseline)

10.0-16.5 g/dL

1

0

4

1

0

0

Neutrophils (<1.0 Giga/L, Black)

1400-8140/μL

4

3

2

1

1

4

Platelets (<100 Giga/L)

120-400 Giga/L

0

0

0

0

0

0

White Blood Cells (<2 Giga/L, Black)

3.5-11/μL

0

1

1

0

0

0

ALT (PCSA >2 ULN)

< 45 U/L

0

1

1

0

0

0

AST (PCSA >2 ULN)

< 45 U/L

0

1

1

0

0

2

Alkaline phosphatase (>1.5 ULN)

13 - 100 U/L

0

0

1

0

0

0

CPK (≥ 3 ULN)

25-90 U/L

1

0

2

2

1

1

Creatinine (≥ 150 μmol/L, adults)

<133 μmol/L

1

0

1

0

0

1

Gamma GT (≥ 3 ULN)

<50 U/L

0

0

1

0

0

0

Glucose (≤ 2.5 mmol/L)

3.6-6.1 mmol/L

0

0

0

0

1

1

Glucose (≥ 2 mmol/L, fasted)

3.6-6.1 mmol/L

1

0

0

0

0

0

Potassium (< 3 mmol/L)

3.5-5.0 mmol/L

0

1

0

0

0

0

Potassium (≥ 5.5 mmol/L)

3.5-5.0 mmol/L

0

0

0

0

1

1

Total bilirubin (≥ 34 μmol/L)

0-17 μmol/L

1

1

0

0

0

0

Total cholesterol (≥ 7.74 mmol/L)

120-240 mg/dL

0

0

0

0

0

0

Triglycerides (≥ 4.6 mmol/L)

0-200 mg/dL

0

0

0

0

0

0

  1. NOTE: N: count of patients; PCSA: Potentially Clinically Significant Abnormality (version 2.2, December 2004); LLN/ULN: Lower/Upper Limit of Normality. For hemoglobin, baseline values <LLN or >ULN are counted normal; for eosinophils, values <LLN are counted as normal. For ALT, AST, ALP, Total Bilirubin, GGT, CPK, baseline values <LLN are counted normal